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Abstract
BACKGROUND: In December 2019, coronavirus (CoV) disease 2019 (COVID-19) was detected in Wuhan, China, 
which is known as severe acute respiratory syndrome CoV 2 (Severe acute respiratory syndrome [SARS]-CoV-2).
AIM: This study attempted a narrative review of the researches about COVID-19 in children.
METHODS: We searched all articles between 2000 and April 2020 in PubMed, Scopus, and ScienceDirect related 
to COVID-19 in children, using the following terms: “COVID-19,” “coronavirus,” “SARS-CoV-2” in combination with 
“pediatrics,” or “children.”
RESULTS: The most common method of transmitting the disease to children was through close contact with family 
members through respiratory droplets. Coinfection is common in pediatric with COVID-19 infection. One of the most 
important transmission routes is oral feces. The severity of the disease was mild or asymptomatic in most children. 
The most common clinical symptoms were fever and cough, and gastrointestinal symptoms were more common in 
children than in adults. Infants and preschoolers had more severe clinical symptoms than older children. The most 
common radiographic findings from the lungs were bilateral ground-glass opacity. Increased procalcitonin and lactate 
dehydrogenase should be considered in children. The use of intravenous immunoglobulin, lopinavir/ritonavir, and 
oseltamivir, along with oxygen therapy, had the greatest effect on improving children’s conditions.
CONCLUSIONS: The most important way to prevent this disease in children is to follow the health tips of family 
members. Although the number of children with the disease is low, children are vulnerable to infection. Antiviral 
medications along with the use of muscle relaxants and oxygen therapy have a great impact on children’s condition.
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Introduction
Coronaviruses (CoV) were discovered in 
1965 and continued to be studied until the mid-1980s. 
Corona’s history of human viruses began in 1965 
when Tyrrell and Bynoe discovered that they could 
pass a virus called B814. The virus was found in the 
human embryonic trachea that was obtained from the 
respiratory tract of an adult with a cold. In the late 1960s, 
Tyrrell, along with a team of virologists working on 
human and animal strains of many viruses, found that 
a group of viruses, including infectious bronchitis virus, 
mouse hepatitis virus, and transmissible gastroenteritis 
virus of swine, they are similar in morphology. This new 
group of viruses was called CoV (the crown because 
of the crown-like appearance on the surface) and was 
later formally accepted as the new genus of viruses [1]. 
CoVs are a large family of viruses and a subset of the 
coronaviridae belonging to the nidovirales order in 
the realm riboviria that range from the common cold 
virus to the more severe causes of diseases such as 
severe acute respiratory syndrome CoV (severe acute 
respiratory syndrome [SARS]), middle east respiratory 
syndrome (MERS), and CoV disease 2019 (COVID19). 
CoVs are a group of viruses that cause diseases in 
mammals and birds. In December 2019, COVID-
19 was detected in Wuhan, China. It has a very high 
transmission capacity and is known as severe acute 
respiratory syndrome CoV 2 (SARS-CoV-2) [2], [3].
Search Strategy
This is a narrative review. According to its nature 
as “narrative,” we did not graduate the articles, but we 
chose the most relevant contributions to the matter. 
This article is a narrative review study and an attempt 
to gather information on all aspects of COVID-19 in 
children. These aspects include virology and genetics, 
physiopathology, epidemiology, clinical manifestations, 
diagnosis, and treatment. The search was conducted 
using five keywords “COVID-19,” “coronavirus,” “SARS-
CoV-2” in combination with “pediatrics,” or “children” 
in PubMed, Scopus, and ScienceDirect among 
articles between 2000 and April 2020. We focused on 
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publications post-year 2000, with emphasis on the past 
10 years, but we did not exclude commonly referenced, 
relevant, and influential older publications. The clinical 
trial, case–control, review, and a meta-analysis study 
of 20 years; 2000–2020 articles, case series, cohort, 
and cross-sectional studies were reviewed. We also 
reviewed the references of each article to include further 
other studies or reports not identified by the search. We 
excluded articles considering the expert viewpoints and 
letters to the editor, which was only one article. A total 
of 85 articles were obtained that resulted in a decrease 
of 64 in the selection of English articles and articles on 
human research.
Virology
All viruses in the Nidovirales order are 
ribonucleic acid (RNA) viruses which are enveloped, 
non-segmented positive-sense RNA viruses. These 
viruses have very large genomes for RNA viruses, 
and Coronavirinae is the largest known RNA genome 
and contains approximately 30 kb genomes [2]. The 
genome of these viruses includes a 5’ cap structure 
with a 3’ poly (A) tail, authorizing it to act as messenger 
RNA (mRNA) to translate replicase polyproteins. The 
replicase gene that encodes nonstructural proteins, 
unlike structural and accessory proteins, which make 
up only about 10 kb of the viral genome, makes up 
two-thirds of the genome, about 20 kb [4]. The CoV 
is specified by club-like spikes from its surface [5]. 
Proteins that contribute to the overall structure of all 
CoVs are the spike (S), envelope (E), membrane 
(M), and nucleocapsid (N), all of which are encoded 
within the 3′ end of the viral genome. In the specific 
case of the SARS CoV, a defined receptor-binding 
domain on S mediates the attachment of the virus to 
its cellular receptor, angiotensin-converting enzyme 
2 (ACE2) [6]. Some CoVs (specifically the members 
of beta-CoV subgroup A) also have a shorter spike-
like protein called hemagglutinin esterase (HE) [7]. 
CoVs can be divided into four genera: Alpha, beta, 
delta, and gamma, of which alpha and beta CoVs 
are known to infect humans [8]. So far seven types of 
CoV have been found in humans: HCoV-229E, human 
CoV OC43 (HCoV-OC43), HCoV-NL63, HCoV-HKU1, 
SARS-CoV, MERS-CoV, and the SARS-CoV-2 or novel 
CoV (2019-nCoV) [9]. SARS-CoV-2 belongs to the 
CoV strain associated with severe acute respiratory 
syndrome (SARSr-CoV) and from the genus beta-
CoV [10]. Recent studies have shown that SARS-
CoV-2, known as a novel virus, can share 79.5% of 
its genetic sequence with SARS-CoV and 96.2% is 
homologous to bat CoV genome named RaTG13. Still, 
the synonymous mutation also results in increased 
T: C transition. This mutation may be due to the loss 
of RNA 3’-to-5’ exoribonuclease function. 2019-nCoV 
shares an ACE2-like entry cell receptor with SARS-
CoV-2, which indicates that SARS-CoV-2 may be more 
infectious to humans than SARS-CoV [11], [12].
Physiopathology
Epithelial cells are the first cells of the human 
body to be infected by CoVs. In vitro studies show that 
CoVs spread from a particular part of these polar cells, 
and this polar spread may be important for the spread 
of infection in vivo. In epithelial cells, CoVs are located 
between the rough endoplasmic reticulum and the 
Golgi body. After the replication of viral particles with 
inverse genetic systems, viruses are transmitted to the 
plasma membrane through the secretory pathway and 
released by exocytosis [13]. As mentioned, CoVs can 
use a number of factors to promote pathogenesis. The 
CoV has four major structural proteins that are: Pike 
(S), membrane (M), envelope (E), and nucleocapsid 
(N) proteins. S glycoprotein is a Class I fusion protein 
that mediates binding to the host epithelial cell receptor. 
M protein enhances membrane curvature and attaches 
to the nucleocapsid and determines the shape of the 
virus. E protein facilitates virus assembly and release 
but has other functions such as ion channel activity in the 
SARS-CoV E protein for pathogenesis. N protein helps 
to bind the viral genome to the replicase-transcription 
complex and wraps the encapsulated genome into 
the viral particles. HE binds sialic acid to surface 
glycoproteins with its acetylesterase activity. These 
activities are thought to increase the entry of S protein 
into the cell and the virus to enter the mucosa [2], [14]. 
It is possible that SARS-CoV-2 is entered to host cells 
through the binding of spike glycoprotein to the enzyme 
two ACE2, sialic acid receptor, transmembrane 2 
serine proteinase (TMPRSS2), and extracellular slow 
cell matrix metalloproteinase (CD147). This condition 
which causes endothelial dysfunction is exacerbated 
by hypoxia and causes thrombosis by increasing blood 
viscosity as well as the signaling pathway associated 
with the hypoxia transcription factor [15].
Epidemiology
On December 31, 2019, the World Health 
Organization (WHO) was informed of a cluster of cases 
of pneumonia of unknown cause detected in Wuhan 
City, Hubei Province, China. This virus was referred 
to as SARS-CoV-2 and the associated disease as 
COVID-19. As of January 5, 2020, 9692 cases were 
identified in China, of which 213 died. Most children 
with COVID-19 have a mild clinical presentation. Few 
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may progress to the lower respiratory infections [16]. 
The incidence of this disease in patients under 18 is 
low (2.4% of total reported) [17]. Since the first report 
of COVID-19 cases from Wuhan to the end of February 
2020, 87,137 people have been diagnosed with the 
disease [18]. The disease is highly contagious, with the 
pandemic reported in the 51st WHO Status Report on 
March 11, 2020 [19]. On April 3, the WHO announced 
that 972,303 people had contracted the disease and 
50,321 had died from the disease [20]. In the first major 
report from China Centers for Disease Control and 
Prevention, which approved 44,672 COVID-19 cases, 
only one death occurred in people under 19 and about 
80% of deaths in adults over 60 years of age [21]. The 
first report of United Stats results among patients with 
COVID-19 shows that 80% of deaths occur in adults 
over the age of 65, with the highest percentage of 
severe consequences among people aged 85 and no 
casualties observed in people under 19 [22]. In Italy, 
only 1.1% of reported primary deaths occurred in people 
<50 years of age, none of whom were children [23].
Current calculations show the incubation 
period of COVID-19 ranging from 1 to 14 days with an 
average of 5–6 days. However, some studies suggest 
that incubation may take up to 24 days, which is higher 
than the WHO statistics. The number of reproductions 
(R0) for SARS-CoV-2 is estimated by current studies 
between 2 and 3, indicating that the epidemic potential 
of this disease is higher than SARS with R0 = 0.8 and 
MERS with R0 = 0.69 [24], [25], [26]. Recent data 
suggest that COVID-19 has a mortality rate of between 
2.3 and 3 [18], [27]. We need to be careful in calculating 
the case fatality rate of COVID-19 (currently at a global 
rate of up to 5%), authenticating that these rates will be 
lower after setting the denominator to reflect the exact 
number of individuals who acquired the infection [26].
Infection sources
The CoV reservoir is different for its variants. 
For SARS, cats were the reservoir of infection, for 
MERS camels, but COVID-19 is still unclear [11]. 
Given that human SARS-CoV-2 has a unique retinoic 
acid receptor recognize motif in S protein, the idea 
that human SARS-CoV-2 is directly from pangolins 
is partially rejected [28]. Some recent studies have 
suggested that pangolins and snakes are likely to host 
SARS-CoV-2 mediators [29], [30].
Transmission route
It is thought that CoVs are transmitted from 
person to person by sneezing and coughing through 
airborne droplets to the nasal mucosa [31], [32]. So 
far, no evidence has been found that COVID-19 is 
transmitted through the air. Still, it has shown that 
respiratory droplets containing the virus, which disperse 
on surfaces, may be responsible for transmitting the 
virus. These surfaces can be as small as the vents [33]. 
In a study by Seyedi et al., it was suggested that the 
virus might also be transmitted through the oral-fecal 
route [34]. Due to the presence of the virus in the feces, 
there is particular concern about the transmission of 
fecal-oral feces, especially for infants and children who 
are not trained in the toilet. Prolonged ejaculation of 
nasal and fecal secretions has important implications 
for community development in childcare centers, 
schools, and homes [35].
In Qiu et al.’s study, which conducted on 36 
children infected with COVID-19, the transmission route 
was through close contact with family members (32 
[89%]) and a history of exposure to the epidemic zone 
(12 [%33]). Eight cases (22%) both had exposure [36]. 
In a study by Chang et al., according to the data 
collected, most infected children (75%) had a home 
contact history [37]. In Xia et al. study, 13 patients in 
children (13.20%, 65%) had a history of close contact 
with family members with COVID-19. Given that most 
reports of the disease have been passed onto children 
through close contact at home with family members, 
it is recommended that family members, especially 
parents, follow the health tips. Coinfection (8/20, 40%) 
is common in pediatric with COVID-19 infection [38]. At 
present, there is no evidence of vertical transmission 
in infants born to mothers with COVID-19 [37], [39] but 
some previous reports have also shown that babies are 
infected in the first few hours after birth [40], [41], [42].
Clinical Characteristics
Clinical presentations
At present, COVID-19 is classified according 
to symptom severity into four levels: Mild, moderate, 
severe, and critical. Mild patients have mild symptoms, 
no symptoms, and no clear radiographic features. 
Patients with severe symptoms have one of three 
criteria: (1) Shortness of breath, respiratory rate (RR) 
>30 times per minute, (2) oxygen saturation <93% in 
ambient air, and (3) partial pressure of oxygen/fractional 
inspired oxygen <300 mmHg. Critically, ill patients 
have one of three criteria: (1) Respiratory failure, (2) 
septic shock, and (3) multiple organ failure [28]. Most 
children with COVID-19 infection are asymptomatic or 
have mild symptoms, no fever, or pneumonia [43], [44]. 
The range of manifestations described in 171 children 
(1 day–15 years) infected with SARS-CoV-2 treated 
at Wuhan Children’s Hospital showed that the most 
common symptoms included cough (in 48.5% of cases), 
pharyngeal erythema (46.2%), and fever (41.5%). Less 
common symptoms were present in <10% of children: 
Diarrhea, fatigue, rhinorrhea, and nasal congestion. It 
was observed in 28.7% of children with tachypnea and 
in 2.2% of children with hypoxemia (oxygen saturation 
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<92% during hospitalization) [45]. In a study of 2214 
children suspected of COVID-19, Dong et al., of 
which 731 children were diagnosed with the disease, 
94 (12.9%), 315 (43.1%), and 300 (41%). They were 
placed in asymptomatic, mild, or moderate cases, 
respectively, accounting for 97% of the confirmed 
cases. The proportions of children classified as 
severe and critical were 2.5% and 0.6%, respectively, 
significantly lower than those observed in adults with 
COVID-19. The point of this study was that infants 
and preschoolers had more severe clinical symptoms 
than older children [46]. In a study by Chang et al., the 
severity of the disease was mostly mild to moderate 
(98%). Only two children (2%) received intensive care. 
Fever occurred in 59% of patients with cough in 46%. 
Gastrointestinal symptoms (12%) were not common. 
About 26% of children are asymptomatic [37]. In a 
study by Qiu et al., 19 (53%) infected children had a 
moderate clinical type with pneumonia; 17 (47%) had 
a mild clinical type, and either was asymptomatic (ten 
[28%]) or had acute upper respiratory symptoms (seven 
[19%]). Common symptoms on admission were fever 
(13 [36%]) and dry cough (seven [19%]). Of those with 
fever, four (11%) had a body temperature of 38·5°C or 
higher, and nine (25%) had a body temperature of 37.5–
38.5°C [36]. Dong et al. study showed the intensity of 
illness by age, and it disclosed that young children, 
particularly infants, were vulnerable to 2019-nCoV 
infection. The content of severe and critical cases was 
10.6%, 7.3%, 4.2%, 4.1%, and 3.0% for the age group 
of <1, 1–5, 6–10, 11–15, and ≥16 years, respectively 
[46]. In Ludvigsson’s study, studies have shown that 
children have so far accounted for 1–5% of COVID-
19 cases, which are often milder than in adults, and that 
mortality is very rare among them. Diagnostic findings 
are similar to those of adults, and fever and respiratory 
symptoms are common, but fewer children appear to 
have severe pneumonia [39]. In Xia et al.’s study, fever 
(12/20, 60%) and cough (13/20, 65%) were the most 
common symptoms [38].
In another study, children with COVID-19 
usually develop fever, fatigue, and cough at the onset 
of the disease, which may be companioned by nasal 
congestion, runny nose, expectoration, diarrhea, 
headache, and so on. Most children had low to moderate 
fever and no fever. Dyspnea of breath, cyanosis, 
and other symptoms was concomitant with systemic 
toxic symptoms, such as weakness or restlessness, 
malnutrition, poor appetite, and less activity after 
1 week and may develop to respiratory failure. Septic 
shock, metabolic acidosis, and irreversible bleeding 
and coagulation dysfunction may occur in these 
severe cases. Characteristics and features of rapid 
RR for the diagnosis of pneumonia in children are 
60 times per minute for <2 months; 50 times per minute 
for 2–12 months, 40 times per minute for 5 years, 
30 times/min for >5 years (after dismissing the effects 
of fever and crying) [47]. According to recent reports, 
children usually have a good prognosis for the disease 
and improve after 1–2 weeks after the onset of mild 
symptoms. The reason for this can be attributed to 
the decrease in ACE2 expression in the lung with 
increasing age. ACE2 plays a role in lung-protective 
mechanisms [48], but it is not clear why children with 
COVID-19 have a milder condition. Adults may be more 
sensitive to conditions such as high blood pressure, 
diabetes, heart disease, or smoking, which can reduce 
their ability to prevent infections. Adults may also be 
more likely to develop an immune overdrive that leads 
to acute respiratory distress syndrome (ARDS). Mild or 
asymptomatic presentation in children may be effective 
in controlling the infection because it can be eliminated 
with existing monitoring.
Laboratory examination
Laboratory samples were taken from 
nasopharyngeal in children with COVID-19 
demonstrated lymphopenia, leukopenia, and 
decreased hepatic and myoglobin enzymes in the first 
phase. Thrombocytopenia may occur [49]. It has been 
shown that lactate dehydrogenase and C-reactive 
protein (CRP) levels increase and decrease in children 
more than adults, respectively, especially in severe 
cases [44], [49]. Elevated erythrocyte sedimentation 
rate and CRP in the second phase, and increased 
dimerization and severe lymphopenia in children with 
severe symptoms can be seen. Procalcitonin (PCT) is 
normal in most cases (PCT<0.5) [16], [47]. In a study 
by Qiu et al., common abnormal laboratory findings in 
children were an increase in creatine kinase MB (11 
[31%]), decreased lymphocytes (11 [31%]), leukopenia 
(seven [19%]), and elevated PCT (six [17%]). The 
variables that were significantly associated with 
COVID-19 intensity were decreased lymphocytes, 
elevated body temperature, and high levels of PCT, 
D-dimer, and creatine kinase MB [36]. In Ludvigsson’s 
study, high inflammatory markers were less common 
in children, and lymphocytopenia was rare. Newborn 
babies have developed COVID-19 [39]. In a study by 
Xia et al., it was suggested that laboratory findings in 
children should be noted for an increase in PCT (16/20, 
80%), which is not common in adults [38].
Imaging features
Chest X-ray (CXR) can also be used to 
diagnose the disease. The most common findings 
for CXR were bilateral ground-glass opacities with or 
without consolidation in the lung periphery. In children 
with severe infection, there have been numerous lobar 
lesions in both lungs [16]. In a study by Li et al., it was 
reported that children had similar but fewer pulmonary 
abnormalities in computed tomography (CT) than 
adults [50]. In a study by Lu et al., the most common 
radiological finding was bilateral ground-glass opacity, 
which was observed in one-third of cases [45]. In 
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another study, the most common radiographic findings 
were ground-glass opacities (48%) [37]. In the study 
by Xia et al. had a total of sxi patients with unilateral 
lung lesions (6/20, 30%), ten people with bilateral lung 
lesions (10/20, 50%), and four cases with no chest CT 
abnormality (4/20, 20%). Consolidation with surrounding 
halo sign was observed in ten patients (10/20, 50%), 
ground-glass opacities were observed in 12 patients 
(12/20, 60%), fine mesh shadow was observed in four 
patients (4/20, 20%), and tiny nodules were observed in 
three patients (3/20, 15%) [38].
Diagnosis
For those who are suspected of having COVID-
19 disease, we must review the epidemiological and 
clinical criteria. Epidemiological criteria are based on 
the presence of the person in the areas infected with 
the virus and clinical criteria are based on clinical 
symptoms, laboratory findings, and radiography [47]. 
To diagnose COVID-19 infection in infants, all of 
the following criteria must be met: (1) At least one 
of the clinical symptoms, including unstable body 
temperature, low activity or poor nutrition, or dyspnea, 
(2) visualization of abnormality in chest radiography 
including bilateral ground-glass opacities, (3) diagnosis 
of infection in the patient’s family or companions, 
and (4) close contact with people who may have or 
definitively have the disease, patients with pneumonia 
without any specific cause or close contact with wild 
animals [41]. Types of samples include upper airway 
specimens (pharynx, nasal swabs, and nasopharyngeal 
secretions), inferior airway specimens (sputum, air 
ducts, and bronchoalveolar lavage fluid), blood, stool, 
urine, and conjunctival secretions. Sputum and other 
lower respiratory tract specimens are highly positive 
for nucleic acids and should preferably be collected 
from them. Combined testing with respiratory, fecal, 
blood, and other specimens is useful to improve the 
diagnostic sensitivity of suspected cases, monitor the 
effectiveness of treatment, and manage post-discharge 
isolation measures [35]. Gene sequencing is one way 
to survey and diagnose COVID-19. RT-PCR, based on 
the S and N genes, is now used to detect viral RNA and 
is known as the gold standard [10], [28], [51], [52].
Treatment
There is no specific antiviral treatment 
recommended for children with COVID-19, but general 
treatment strategies for children include bed rest and 
supportive therapies. Affected children should get 
enough calories and water. Preservation of water 
and electrolytes, homeostasis, and strengthening of 
psychotherapy in older children should be performed 
if necessary [43], [39]. In one study of serine protease 
TMPRSS2, which is required for protein S priming, it 
was suggested that camostat mesylate as a protease 
serase inhibitor could prevent COVID-19 from entering 
the lung cell [53]. Children with COVID-19 who 
breathe through a ventilator often need sedatives, 
painkillers, and even muscle relaxants to prevent lung 
damage caused by the ventilator. Note that, antibiotics 
and corticosteroids should be avoided except in 
some cases. Corticosteroids can be used in limited 
cases, such as the occurrence of ARDS on CXR, 
septic shock, encephalopathy, and hemophagocytic 
syndrome. Some studies recommended drug and 
dose is intravenous methylprednisolone (1–2 mg/kg/
day) for only 3–5 days [16], [47]. In the study of Shen 
ibuprofen was used orally at a dose of 5–10 mg/kg and 
acetaminophen orally at a dose of 10–15 mg/kg [16]. 
In Ludvigsson’s study, the proposed treatment included 
oxygen supply, inhalation, nutritional support, and fluid 
retention, and electrolyte balance [39].
Therapeutics and drugs
Antiviral therapy
Numerous studies have been conducted 
on drugs that affect the treatment of COVID-19 in 
children, but so far, no antiviral drug has led to definitive 
treatment. In a study by Chen et al. as well as Shen and 
Yang study, some effective antiviral drugs to improve 
the condition of children with the disease include 
interferon-α2b nebulization 100,000–200,000 IU/kg 
for mild cases, and 200,000–400,000 IU/kg for severe 
cases, 2 times/day for 5–7 days [16], [47]. Lopinavir/
ritonavir (200 mg/50 mg), the recommended doses: 
Weight 7–15 kg, 12 mg/3 mg/kg; weight 15–40 kg, 
10 mg/2.5 mg/kg; and weight >40 kg, 400 mg/100 mg as 
an adult each time, twice a day for 1–2 weeks [47], [54]. 
In Wang et al. study, food and drug administration-
approved antiviral drugs in vitro, especially remdesivir 
and chloroquine, have been effective in controlling 
COVID-19 infection in vitro [55]. In Tang et al. study, 
medicines for treating infected children include 
oseltamivir, ribavirin, interferon, Kaletra, and traditional 
Chinese medicine [56]. In the study by See et al., none 
of the children needed antiviral therapy [57]. In the 
study of Liu et al., in six children, ribavirin was used 
in two patients and oseltamivir in six children [44]. In a 
study of nine children by Rahimzadeh et al., oseltamivir, 
lopinavir, and ritonavir were used for treatment, with the 
role of oseltamivir being very pronounced. However, 
there was no use of ribavirin [17]. In the study of Shen 
et al., arbidol and oseltamivir were used [16]. In Qiu 
et al. study, all children received interferon alpha twice 
daily by aerosolization and 14 (39%) infected children 
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received twice daily lopinavir-ritonavir syrup [36]. In 
another study, double-stranded RNA activated caspase 
oligomerizer (DRACO) and immucillin-A, which inhibit 
RNA synthesis, have been suggested as antiviral drugs 
for the treatment of this disease (Table 1) [49].
Antibody therapy
Intravenous immunoglobulin can be used 
in severe cases, but the effect should be further 
investigated. The recommended dose is 1.0 g/kg for 
2 days or 400 mg/kg for 5 days [14], [16], [17], [44], [56]. 
It has been shown that monoclonal antibodies (from 
human brain plasma, animal, or manufactured plasma) 
affect glycoprotein S, inhibiting the penetration of CoVs 
into human cells and reducing mortality in patients 
infected with SARS-CoV-2 (Table 1) [58].
Antibacterial therapy
In Rahimzadeh et al. study, meropenem, 
vancomycin, and chloroquine were used as an 
antibacterial therapy [17]. In the Lu et al. study, the 
combination of sirolimus plus dactinomycin in pediatric 
treatment has been suggested [40]. In a study by 
Zimmermann and Curtis, it was noted that the use of 
chloroquine in vitro is effective against SARS-CoV-2, 
but further studies have been recommended in vivo 
(Table 1) [58].
Other drugs
In Lu et al. study, two-drug combinations 
(mercaptopurine plus melatonin, and toremifene 
plus emodin) are the drugs suggested for pediatric 
treatment [40]. Scutellariae Radix, Armeniacae Semen 
and Coicis Semen have been suggested in a study 
examining herbal medicines used to treat COVID-19 in 
children (Table 1) [59].
Oxygen therapy
In hypoxia in children, an oxygen mask or 
nasal catheter should be used immediately to adjust 
the oxygen concentration. In many studies, using 
oxygen therapy or mechanical ventilators have 
been effective in improving patients’ well-being [16], 
[17], [36], [44], [47]. In Lu et al. study, infants with 
ARDS, high-dose pulmonary surfactant, inhaled 
nitric oxide, high-frequency oscillatory ventilation, 
and extracorporeal membrane lung may be highly 
recommended (Table 1) [40].
Plasma therapy
Studies that show that serums from COVID-19 
improved patients may be useful for the treatment of 
COVID-19 infection [40].
Conclusions
The current prevalence of COVID-19 is 
widespread in the world and the WHO has identified 
it as one of the public health concerns. The disease is 
highly contagious because most children with COVID-
19 have close contact with family members, including 
their parents, increasing public health information and 
following these tips can have a significant impact on 
reducing children’s susceptibility to the disease. Although 
the number of children with the disease is low, children 
are vulnerable to infection. Antiviral medications for the 
treatment of children Along with the use of pain relievers, 
muscle relaxants, and oxygen therapy have a great impact 
on children’s condition. The role of serum therapy should 
also be taken seriously in future COVID-19 treatment.
Table 1: Different types of treatments of children with COVID-19 according to various studies
Studies Treatments
Antibacterial therapy Antiviral therapy Antibody therapy Oxygen therapy Plasma therapy Other medications
Shen et al. [16] No Arbidol, oseltamivir, 
interferon-α nebulization, 
interferon-α2b nebulization
Yes (Intravenous 
immunoglobulin)
Yes No Ibuprofen, acetaminophen, 
intravenous methylprednisolone
Rahimzadeh et al. [17] Meropenem, vancomycin, 
chloroquine
Lopinavir, oseltamivir, ritonavir No Yes No No
Liu et al. [44] Yes Ribavirin, oseltamivir Yes (Intravenous 
immunoglobulin)
Yes No Glucocorticoids
Chen et al. [47] No Interferon-α2b nebulization, 
lopinavir/ritonavir
Yes (Intravenous 
immunoglobulin)
Yes No Intravenous methylprednisolone
Zimmermann and 
Curtis [49]
Chloroquine Lopinavir/ritonavir, DRACO, 
and immucillin-A
Yes (Intravenous 
immunoglobulin)
Yes Yes No
Tang et al. [56] No Ribavirin, oseltamivir, 
interferon-α2b nebulization, 
lopinavir/ritonavir
No No No Traditional Chinese medicines
Lu and Shi [40] Combination of sirolimus and 
dactinomycin
No Yes Yes Yes Mercaptopurine plus melatonin, 
toremifene plus emodin, and 
inhaled nitric oxide
Qiu et al. [36] No Interferon alpha twice daily by 
aerosolization and twice-daily 
lopinavir-ritonavir syrup
No Yes No No
Ang et al. [59] No No No No No Scutellariae Radix, Armeniacae 
Semen and Coicis Semen
COVID-2019: Coronavirus disease 2019.
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